Aplastic Anemia
Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation.
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…
Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT: a 20-year single-center experience
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) clones are detected in up to 60% of patients with aplastic anemia (AA); however, their prognostic impact remains incompletely defined, particularly in the context of frontline immunosuppressive therapy (IST) or…
Pregnancy after hematopoietic stem cell transplant: an international multicenter study
Key Points A large retrospective study evaluating association between pregnancy after HCT with both conditioning protocols and assisted reproduction. Findings include that some protocols appear more sterilizing than others and the impact of assisted reproduction is substantial…
Clonal Signatures of Telomere Biology Disorders
Abstract Purpose of Review In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs)…
Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia
Abstract Background Clonal hematopoiesis (CH) is a feature of severe aplastic anemia (SAA), but its clinical significance is debated. Methods We integrated longitudinal clinical and CH data from patients with SAA treated with immunosuppression plus eltrombopag (IST-EPAG) in a…
Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia
Key Points Frontline eltrombopag plus IST is cost-effective compared with IST alone for adults with severe aplastic anemia. Incremental net monetary benefit per patient treated with frontline eltrombopag is ∼$64 000. Abstract The randomized phase 3 RACE trial demonstrated…
The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation
ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment for patients with high-risk hematologic malignancies. Over the last decade, gut microbiota composition during allo-HCT has been associated with patients' outcomes. Treatment-related…
Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study
Distinguishing acquired (idiopathic/immune) severe aplastic anemia aplastic anemia: